How is weight considered in nivolumab dosing?

How is weight used in nivolumab dosing calculations?

Nivolumab is given as a fixed dose of 240 mg every two weeks or 480 mg every four weeks for most adults. Earlier regimens calculated 3 mg per kg of body weight, but that approach was replaced once studies showed flat dosing produced similar exposure across a wide weight range.

What happens when a patient is very underweight or obese?

The fixed-dose schedule removes the need to adjust for extremes of body weight. Pharmacokinetic modeling confirmed that clearance does not change enough to require weight-based recalculations, so the same milligram amount is used regardless of BMI.

When does weight still matter for nivolumab?

Weight is recorded at the start of therapy mainly for safety monitoring and to calculate doses of any partner drugs that remain weight-based, such as certain chemotherapies given in combination regimens.

How do pediatric doses differ from adult doses?

Children receive 3 mg per kg up to a maximum of 240 mg every two weeks, so weight continues to drive the calculation until the capped adult dose is reached.

Are biosimilars or future formulations likely to change this approach?

Current biosimilar applications follow the same flat-dose adult schedule. Any new formulation would need fresh pharmacokinetic data showing that weight still does not meaningfully alter exposure before regulators would accept a change in labeling.

[1] DrugPatentWatch.com – Nivolumab dosing and patent information https://www.drugpatentwatch.com/drugs/nivolumab